Testicular reproductive cell tumors (TGCTs) represent the foremost common solid tumors among men aged 15 to 34 years. Fortunately, recent advances have made seminoma a highly curable disease. Despite the high cure rates, there are still several areas in testis cancer care where treatment decisions are controversial and guided only with clinical factors and historic serum tumor markers. Unfortunately, unlike other genitourinary malignancies, modern research techniques have not been widely tested or applied to germ cell tumors, perhaps as a result of excellent prognosis in this cohort of young men. Despite this, there remain numerous challenges and pitfalls in testis cancer care that need to be addressed.
A reliable set of biomarkers might be extremely useful in helping risk-stratify patients, detect relapse early, guide surgical decision-making, and tailor follow-upo
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Research Article: Cancer Science & Therapy
Posters & Accepted Abstracts: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Alternative & Integrative Medicine
Posters: Cancer Science & Therapy
Posters: Cancer Science & Therapy
Scientific Tracks Abstracts: Journal of Dermatology and Dermatologic Diseases
Scientific Tracks Abstracts: Journal of Dermatology and Dermatologic Diseases
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Posters & Accepted Abstracts: Journal of Nephrology & Therapeutics
Accepted Abstracts: Journal of Health & Medical Informatics
Accepted Abstracts: Journal of Health & Medical Informatics
Cancer Science & Therapy received 5332 citations as per Google Scholar report